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G protein-coupled receptor (GPCR)
GPRC6A
Signal transduction
Dimerizationa b s t r a c t
Investigation of post-translational modiﬁcations of receptor proteins is important for our under-
standing of receptor pharmacology and disease physiology. However, our knowledge about post-
translational modiﬁcations of class C G protein-coupled receptors and how these modiﬁcations reg-
ulate expression and function is very limited. Herein, we show that the nutrient-sensing class C G
protein-coupled receptor GPRC6A carries seven N-glycans and that one of these sites modulates sur-
face expression whereas mutation of another site affects receptor function. GPRC6A has been spec-
ulated to form covalently linked dimers through cysteine disulﬁde linkage in the extracellular
amino-terminal domain and here we show that GPRC6A indeed is a homodimer and that a disulﬁde
bridge between the C131 residues is formed.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction G -coupled response and production of inositol phosphate mes-The G protein-coupled receptor class C, group 6, member A
(GPRC6A) belongs to the class C of G protein-coupled receptors
(GPCRs), which are characterized by large amino terminal extracel-
lular domains (ECDs) [49,54], comprised of a Venus-ﬂytrap (VFT)
domain and a cysteine-rich domain (CRD). The VFT domain is
responsible for ligand binding whereas the CRD is important for
signal transfer to the transmembrane domain [18,24,32,55]. The
GPRC6A receptor is activated by a promiscuous range of basic
and small aliphatic L-a-amino acids, in addition to calcium that
either directly activates or co-activates the receptor, leading to aq
senger molecules [5,20,23,39,41,56]. Other ligands as well as path-
ways like Gs and Gi have been proposed [12,34,35,39,40,41,42],
however we have been unable to conﬁrm this [20]. The physiolog-
ical function of the receptor has so far only been characterized via
knockout mice, which have shown interesting phenotypes like
diet-induced obesity, feminization, glucose intolerance, and insulin
resistance identifying this receptor as a potential drug target in
metabolic disorders [6,7,38].
To better understand the pharmacology and regulatory aspects
of GPCRs much research is focused on the role of post-translational
modiﬁcations (PTMs) and oligomerisation of these receptors. PTMs
regulate many essential processes within the cell, preparing the
synthesized protein for folding, trafﬁcking, etc. by adding e.g. oli-
gosaccharides (glycans), phosphorylation, ubiquitination, and
palmitoylation at speciﬁc residues. Even small errors in the regula-
tion of these PTMs may result in misfolded and/or dysfunctional
proteins. N-glycosylation is one of the most common types of gly-
cosylation, resulting from the attachment of a sugar moiety to an
asparagine (Asn, N) placed in the consensus sequence: N-X-S/T,
X– P. The role of glycosylation is not well understood for GPCRs,
however research has clearly shown the importance of N-glycans
in surface targeting and second messenger production
[9,15,16,25,26,29,30,31,57]. Characterization of both rat and
mouse GPRC6A has revealed that the receptor is N-glycosylated
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[23,56]. However the speciﬁc glycosylation pattern is still
unknown as well as the role of this PTM on receptor pharmacology.
Another important factor for receptor regulation and pharma-
cology is subunit stoichiometry. Class C receptors are regarded as
dimers or for the GABAB receptor even tetramers [3,8,11,13].
Dimer- or oligomerization of receptors can be mediated via cova-
lent disulﬁde bridges [3,45,48,53] or via non-covalent association
of the lipophilic transmembrane domains [4,10,17,22,33], interac-
tions between the extracellular domains [1] or C-terminus interac-
tions [28,36]. These interactions can affect the pharmacological
diversity, signal transduction, ontogeny, internalization and
ligand-promoted regulation of GPCRs emphasizing the importance
of this phenomenon [52]. mGluR1, mGluR2, and mGluR5 form
homodimer disulﬁde bridges in positions C140, C121 and C129,
respectively [13,44,46]. The CaSR, which is the closest homolog
to GPRC6A, has also been shown to form homodimers by bridging
the cysteine residues C129 and C131 [23,45]. However, disruption
of these disulﬁde bridges seems not to interrupt the dimerization
questioning the role of the cysteine linkage [44,45]. Evidence based
on Western blots showing bands of dimer size, which are con-
verted into monomer bands under reducing conditions with addi-
tion of dithiothretiol (DTT) suggest that GPRC6A also forms a
homodimer [23,56]. We therefore sat out to investigate if GPRC6A
is a dimer, if such a disulﬁde bridge is present, and if it affects the
dimerization of GPRC6A. Collectively, we wished to identify spe-
ciﬁc N-glycosylation and disulﬁde bridge residues, with the aim
of increasing our understanding of the regulation and pharmacol-
ogy of the GPRC6A receptor.2. Materials and methods
All chemicals were purchased from Sigma–Aldrich unless other-
wise speciﬁed.
2.1. GPRC6A constructs
Upon alignment with other class C GPCRs two cysteine residues
possibly involved in dimer disulﬁde linkage were identiﬁed. The
cysteine residues were mutated to alanine, alone and together,
resulting in a total of three constructs; C122A, C131A and
C122A + C131A made by Genscript (Piscataway, NJ, USA) (Fig. 1).
Nine asparagine residues were predicted to carry in vivo glycosyla-
tions by the use of NetNGlyc 1.0 Server at www.cbs.dtu.dk and
these were mutated to glutamine; N86Q, N121Q, N259Q, N332Q,
N378Q, N452Q, N555Q, N567Q and N733Q by Genscript (Piscata-
way, NJ, USA) (Fig. 1 and Table 1). The previously described N-ter-
minally c-myc-tagged rat GPRC6A receptor inserted into a pEGFP-
N1 vector was used as template for the introduced mutations [56].
The N-terminally hemagglutinin (HA)-tagged rGPRC6A receptor
was generated by replacing the c-myc-epitope with an HA-epitope
in the c-myc-rGPRC6A-pEGFP-N1 construct as previously
described for the GABAB receptors [36]. N-terminally HA-tagged
5-HT2A receptor (HA-5-HT2A) was purchased from the Missouri
S&T cDNA resource center, USA.
2.2. Transfection
Transient transfection of HEK-293T cells was performed in
white 96-well plates (Corning, Corning, NY, USA) for Enzyme-
Linked Immunosorbent Assay (ELISA), white 96-well plates (Fal-
con, Corning, NY, USA) for dimerization assay and clear 96-well
plates (Greiner Bio-One GmbH, Frickenhausen, Germany) for func-
tional signaling assays, whereas transfection in 60 mm dishes was
performed for the Western blot experiments. For transfection in96-well plates a DNA:Lipofectamine 2000 ratio (Life Technologies,
Nærum, Denmark) of 0.5 lg:0.25 ll/well was used. Plates were
coated with poly-D-lysine before addition of DNA and cells. For
each well 0.5 lg of DNA was prepared and diluted in 25 ll Opti-
MEM. Lipofectamine 2000 was diluted in 25 ll Opti-Mem and then
mixed with the DNA solutions and left at room temperature (RT)
for 20 min. Plates were washed with 100 ll/well of Dulbecco’s
phosphate buffered saline (DPBS) cat. No. 14190169 (Life Technol-
ogies, Nærum, Denmark) and 50 ll of DNA complexes were added
to each well. 12,500 HEK-293T cells suspended in Dulbecco’s Mod-
iﬁed eagle medium (DMEM) cat. No. 31966047 (Life Technologies,
Nærum, Denmark) + 10% dialyzed fetal bovine serum (dFBS) (Life
Technologies, Nærum, Denmark) were added to each well. For
Western blotting experiments 500,000 HEK-293T cells were
seeded in a 60 mm culture dish. After overnight incubation 4 lg
of DNA and 7.5 ll Lipofectamine 2000 were used to transfect cells
as described by the manufacturer. Cells were used 24–48 h post
transfection.
2.3. Quantiﬁcation of receptor expression
Total and cell membrane receptor expression levels were deter-
mined by ELISA utilizing a c-myc epitope fused to the N-terminal
of rGPRC6A [56]. The GABAB system was applied as control for cor-
rect cell surface expression. Cells were treated as follows: Media
was removed and 50 ll/well of DPBS + 4% paraformaldehyde was
added and incubated for 5 min at RT. The wells were washed twice
with DPBS + 1 mM CaCl2. In wells where the total amount of c-
myc-tagged receptor were to be determined, 50 ll of 0.1% Triton-
X in DPBS was added and incubated at RT for 5 min. The Triton-
treated wells were further washed two times with DPBS. All wells
were blocked with 100 ll/well 3% skim milk in DPBS for at least
30 min. After blocking, 75 ll/well of 1:1000 anti-c-myc antibody
(Life Technologies, Nærum, Denmark) or 1:1000 anti-HA antibody
(Nordic Biosite, Copenhagen, Denmark) were added and incubated
at RT for 45 min. Following antibody incubation, wells were
washed twice with DPBS + 1 mM CaCl2 before 75 ll of 1:1500 per-
oxidase labeled horse anti-mouse IgG (Vector Laboratories Inc.,
Burligame, CA, USA) was added and also incubated for 45 min.
Wells were then washed four times with 100 ll/well of blocking
solution followed by another four washes with 100 ll/well of
DPBS + 1 mM CaCl2. 70 ll of DPBS + 1 mM CaCl2 was added to each
well and prior to plate reading, 10 ll/well of SuperSignal ELISA
Femto Maximum Sensitivity Substrate (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) was added. The chemiluminescence was mea-
sured immediately after substrate addition on an EnSpire micro-
plate reader (PerkinElmer Life and Analytical Sciences, Waltham,
MA).
2.4. Functional inositol monophosphate accumulation assay
Activation of the GPRC6A receptor was determined by an inosi-
tol monophosphate accumulation assay. Cells were washed for
2  2 h with Wash Buffer (Hank’s balanced salt solution (HBSS)
cat. No. 14175129 (Life Technologies, Nærum, Denmark) + 20 mM
HEPES + 1 mg/ml bovine serum albumin (BSA) pH 7.4) prior to
ligand stimulation. L-ornithine was diluted in ligand buffer
(HBSS + 20 mM HEPES + 40 mM LiCl + 1 mM CaCl2 and 1 mM
MgCl2 pH 7.4) and cells were stimulated for 1 h at 37 C. Stimula-
tion buffer was then removed and cells were lysed by adding 30 ll
of Conjugation & Lysis buffer (Cisbio Bioassays, Codolet, France) to
each well and incubated at RT for at least 30 min. 10 ll of cell lysis
were transferred to a 384-well plate and 10 ll of the detection
solution composed of 2.5% anti-IP1 cryptate Tb and 2.5% IP1-d2
(IP-One HTRF kit, Cisbio, Codolet, France) dissolved in assay buffer
(HBSS + 20 mM HEPES + 1 mM CaCl2 and 1 mMMgCl2) were added
Fig. 1. Schematic representation of the rat GPRC6A showing locations of putative N-linked glycosylation sites as well as possible disulﬁde bridge residues. Each amino acid
residue is represented by a circle. Asparagine residues predicted to be glycosylated are colored in red (N86, N121, N259, N332, N378, N452, N555, N567, and N733). Residues
marked in blue have not been investigated due to a negative prediction of in vivo glycosylation (N85 and N304) or because they are positioned in the intracellular part of the
receptor (N857 and N889). Possible conserved cysteines are in green (C122 and C131).
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at 615 and 665 nm were measured on an EnVision platereader
after excitation at 340 nm (PerkinElmer Life and Analytical Sci-
ences, Waltham, MA). The FRET ratios (665 nm/615 nm) were then
converted to the concentration of IP1 by use of a provided standard.2.5. Dimerization assay by homogenous time-resolved Förster
resonance energy transfer (HTRF)
HTRF experiments were carried out using a combination of a
Tb3+-labeled anti-HA antibody, as the donor ﬂuorophore, and a
Table 1
Prediction of N-glycosylation of rGPRC6A using the NetNGlyc 1.0 Server. Potential
threshold = 0.5.
Position Motif Potential Result
85 NNSS 0.4166 
86 NSSL 0.5433 +
121 NCSR 0.6523 +
259 NQTL 0.5910 +
304 NWST 0.3219 
332 NMSS 0.7583 +++
378 NYSQ 0.5581 +
452 NVTF 0.5899 +
555 NETD 0.7071 ++
567 NETH 0.5682 +
733 NTSL 0.5944 +
857 NYSA 0.5162 +
889 NKTA 0.5512 +
Fig. 2. Rat GPRC6A is glycosylated. Membranes from HEK-293T cells transiently
transfected with c-myc-tagged rGPRC6A receptor (WT) or empty plasmid (mock)
were detected with anti-c-myc antibody and visualized with anti-mouse HRP-
conjugate and ECL reagent. Mock-transfected cells did not show any signiﬁcant
immunoreactivity. Cells transfected with WT receptor show a dense band at
230kDa and a smaller band at 100kDa, representing dimeric and monomeric
forms, respectively. Treatment with the deglycosidase PNGase F resulted in lower
migrating bands (both dimeric and monomeric) of the receptor. The blot is a
representative of two independent experiments.
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Cisbio Bioassays (Codolet, France) as previously applied [8,27].
Cells were, after transfection, washed once in cold Wash Buffer
and incubated with the ﬂuorophore-coupled antibodies (1 nM
anti-HA-Tb and 50 nM anti-c-myc-d2) diluted in Wash Buffer for
25 h at 4 C. The HTRF signal was measured at 665 nm after exci-
tation at 340 nm (Fig. 4A) on an EnVision Multilabel Reader (Perk-
inElmer, Waltham, MA).
2.6. Membrane preparation
Cells were kept on ice and washed once with ice-cold DPBS.
800–1000 ll of RIPA Lysis buffer (50 mM TrisHCl, pH 7.4;
150 mM NaCl; 1% Nonidet P-40; 0.5% sodium deoxycholate and
0.1% SDS) were added. For reducing conditions the RIPA buffer
was supplied with 1 mM DTT and 0.5% v/v b-mercaptoethanol. Cell
lysates were transferred to tubes which were incubated for 2 h at
4 C on a rotator. Tubes were then centrifuged at full speed for
30 min at 4 C in a tabletop centrifuge. Supernatant was trans-
ferred to a fresh tube and protein concentration was determined
by performing a Bio-Rad Protein Assay (Bio-Rad Laboratories Inc.,
Copenhagen, Denmark) according to the manufacturer’s protocol.
2.7. Western blotting
Protein samples were mixed with 4 loading buffer (NuPage
LDS Sample buffer) and 40 lg of protein were loaded onto a
NuPAGE NOVEX 3–8% Tris–acetate gel (Life Technologies, Nærum,
Denmark). Samples were run for 75 min at 200 V in 1 NuPAGE
Tris–acetate SDS Running Buffer (Life Technologies, Nærum, Den-
mark). Proteins were transferred to Amersham Hybond-ECL mem-
branes (GE Healthcare, Brøndby, Denmark) for 90 min at 30 V in
ice-cold Tris–glycine buffer (25 mM Tris and 192 mM glycine) with
15% ethanol (EtOH). Membranes were blocked for at least 20 min
in 5% skim milk in DPBS before adding 1:1000 anti-c-myc antibody
(Life Technologies, Nærum, Denmark) and were then incubated at
RT for 1 h or at 4 C overnight in a wet chamber. Membranes were
then washed four times in 1 Tris Buffered saline with 0.2%
Tween-20 (TBST) and incubated with 1:15,000 secondary peroxi-
dase labeled horse anti-mouse IgG (Vector Laboratories Inc., Burli-
game, CA, USA). Following four times washing in TBST the
membranes were developed using Amersham ECL Prime Western
Blotting Detection reagent (GE Healthcare, Brøndby, Denmark).
Pictures were taken using the FluorChem HD2 System (ProteinSim-
ple, Santa Clara, CA, USA). Exposure times were optimized for the
individual experiments.2.8. Deglycosylation
Wild type GPRC6A protein samples were treated with PNGase F
to remove N-glycans. Approximately 40 lg of protein were added
2 ll of PNGase F corresponding to one unit and incubated at
37 C for 2 h.
2.9. Data analysis
Data obtained were analyzed using GraphPad Prism v. 5 (Graph-
Pad Software, San Diego, CA) and ImageJ v. 1.48 (Wayne Rasband,
National Institutes of Health, USA). Statistical analysis (one-way
analysis of variance (ANOVA) followed by Dunnett’s test) was per-
formed where appropriate and is indicated in the ﬁgure captions.
Statistical signiﬁcance was determined at the following levels:
⁄P < 0.05, ⁄⁄P < 0.01 and ⁄⁄⁄P < 0.001.
3. Results
3.1. Identiﬁcation of N-linked glycosylation sites on rGPRC6A
To verify rGPRC6A receptor glycosylation in HEK-293T cells, we
transfected cells and treated with PNGaseF. The results showed a
marked downward shift in molecular weight for both monomeric
and oligomeric bands compared to control, suggesting the pres-
ence of N-linked oligosaccharides on rGPRC6A (Fig. 2).
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X-S/T) we used the NetNGlyc 1.0 prediction server (prediction ser-
ver at Center for Biological Sequence Analysis, Technical University
of Denmark). Eleven of 13 possible sites were returned with a posi-
tive score suggesting N-glycosylation (Table 1). The two residues
predicted not to carry any N-glycans were not investigated further
as well as the two sites (N857 and N898) that were localized intra-Fig. 3. Effects of mutation of putative N-glycosylation sites in rGPRC6A. (A) 40 lg of pro
and fractioned on a 3–8% Tris–acetate gel by SDS–PAGE. Western blotting was done using
each lane a major band at 220kDa is seen corresponding to multimer receptors. For
corresponding to core and fully glycosylated monomeric receptor forms. For N86Q and
experiments. (B and C) ELISA was used to determine surface and total expression for wild
and black bars show total expression. Data are presented as means ± S.E.M. of at least
Signiﬁcant differences fromWTwere calculated by a one-way ANOVA followed by Dunne
indicated constructs 24 h prior to experiments where they were stimulated with L-Orn for
France). Data are normalized to wild-type (WT) IP1 accumulation. Data are means ± S.
triplicates.cellularly. The remaining nine Asn residues were mutated to gluta-
mine (Gln, Q) and analyzed on SDS–PAGE. Membrane preparations
from HEK-293T cells, transiently transfected with either wild-type
(WT) or mutant rGPRC6A receptors, showed subtle but clear
migration differences (Fig. 3A). The bands at 220kDa represent
receptor dimers/oligomers whereas the two bands seen around
100kDa are monomeric forms of the receptor corresponding totein from membrane extracts of transiently transfected HEK-293T cells were loaded
an anti-c-myc antibody followed by anti-mouse HRP-conjugate and ECL reagent. For
all receptors except N86Q and N555Q, two bands are seen at 90 and 110kDa
N555Q only the lower band is seen. The blot is representative of ﬁve independent
-type (WT) and indicated mutants of rGPRC6A. White bars show surface expression
four independent experiments performed in triplicates and are normalized to WT.
tt’s post-test (⁄P < 0.05, ⁄⁄⁄P < 0.001). (D) HEK-293T cells transiently transfected with
1 h. IP1 accumulation was detected by the IP-One HTRF assay from Cisbio (Codolet,
D. of a single representative experiment out of 5 individual repeats performed in
Fig. 4. Detection of rGPRC6A dimers on the cell surface. (A) Principle of the HTRF protein–protein interaction system. Two receptor subunits carry different epitope tags at
the N-termini and are incubated with antibodies conjugated with donor and acceptor ﬂourophores. This allows detection of a FRET signal if the respective subunits are in
close proximity. 6A: GPRC6A. (B) Transiently transfected HEK-293T cells were labeled with a combination of anti-HA-Tb and anti-c-myc-d2 antibodies for 25 h and the HTRF
signal was measured as described in Section 2. Upon co-transfection of HA and c-myc labeled rGPRC6A a FRET signal is generated demonstrating dimerization of rGPRC6A.
Data are presented as means ± S.E.M. of at three independent experiments performed in triplicates and are normalized to mock. (C) ELISA was used to determine surface
expression for the indicated constructs. White bars are detection of c-myc-tagged constructs, whereas gray bars represent HA-tagged constructs. Data are presented as
means ± S.E.M. of at three independent experiments performed in triplicates and are normalized to c-myc-rGPRC6A or HA-rGPRC6A.
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We believe that the two bands with a size of approximately
100kDa probably represent the fully and the core glycosylated
forms of the monomeric receptor. N86Q and N555Q interestingly
only display the lower band. Bands from N86Q and N733Qmutants
migrates like WT, whereas the N121Q, N259Q, N332Q, N378Q,
N452Q, N555Q and N567Q mutants all migrate with a 5kDa
lower weight compared to WT indicating the loss of an N-glycan.
These data suggest a total of seven N-glycosylations on rGPRC6A.
3.2. Mutation of putative N-linked glycosylation sites on rGPRC6A
affects receptor expression
Next we investigated if the mutations had an effect on receptor
expression. Cells were transiently transfected with the indicated c-
myc-rGPRC6A receptor constructs and ELISA was used to analyzesurface and total GPRC6A receptor expression. Only the N86Q
and N555Q mutants showed an altered expression level compared
to WT, which was reduced approximately 50% for both surface and
total expression (Fig. 3B and C). For N555Q this could be due to loss
of the N-glycan whereas mutation of N86 did not alter migration of
the receptor. The reduced expression of the N86Q mutant can
therefore not be explained by a changed glycosylation pattern.
3.3. Mutation of putative N-linked glycosylation sites on rGPRC6A
affects receptor function
Receptor function is often linked with expression and we there-
fore assayed the functional responses of the different mutants
using the IPOne accumulation assay that measures Gq-activation.
Most mutants showed similar activation proﬁles as the wild-type
receptor, except N86Q and N555Q, which had signiﬁcantly reduced
594 L. Nørskov-Lauritsen et al. / FEBS Letters 589 (2015) 588–597activity at the maximum concentration of agonist (Fig. 3D). The
lower expression levels of these two mutants and the loss of glyco-
sylation could indicate that intracellular trapping/degradation
causes this reduction. Interestingly, we observed that the N567Q
mutant increased the maximal response by more than 20% com-
pared to wild-type (Table 2), which is not caused by an increased
surface expression (Fig. 3B and C).
3.4. Identiﬁcation of cysteine residue involved in rGPRC6A dimer
formation
To determine if rGPRC6A is indeed a dimer an HTRF assay was
conducted using an anti-HA antibody labeled with a donor ﬂuoro-
phore and an anti-c-myc labeled acceptor ﬂuorophore (Fig. 4A).Table 2
L-Orn signaling parameter estimates for rGPRC6A Asn mutant receptors. IP1 accumu-
lation was detected by the IP-One HTRF assay from Cisbio (Codolet, France). No
statistical signiﬁcant differences compared to WT were observed.
EC50
(lM)




WT 200 3.70 ± 0.19 100 100
N86Q 386 3.41 ± 0.09 40 ± 8.3 74
N121Q 289 3.54 ± 0.07 72 ± 16 57
N259Q 122 3.91 ± 0.09 59 ± 8.8 70
N332Q 205 3.69 ± 0.19 67 ± 13 47
N378Q 156 3.81 ± 0.10 69 ± 11 50
N452Q 177 3.75 ± 0.07 83 ± 29 77
N555Q 338 3.47 ± 0.07 34 ± 13 97
N567Q 141 3.85 ± 0.25 123 ± 17 108
N733Q 294 3.53 ± 0.16 62 ± 11 73
Fig. 5. Effects of mutation of putative VFT disulﬁde sites in rGPRC6A. (A) Alignment of ra
(blue), the calcium-sensing receptor (CaSR) and the eight metabotropic glutamate recep
CaSR and mGluRs (shown in italic). The conserved cysteines among the receptors are mar
involved in formation of disulﬁde bridges (red). Alignment performed using MEGA v.6.06
formation for rGPRC6A. Membranes from transiently transfected HEK-293T cells were b
230kDa and a smaller band at 100kDa, as previously shown. Mutation of C122A did n
C122A, the upper dimer band was markedly reduced whereas the lower monomeric ban
experiments. (C and D) ELISA was used to determine surface and total expression for w
whereas black bars show total expression. Data are presented as means ± S.E.M. of at leas
Signiﬁcant differences fromWT were calculated by a one-way ANOVA followed by Dunne
indicated constructs were stimulated with L-Orn for 1 h. IP1 accumulation was detect
normalized to WT IP1 accumulation. Data are means ± S.D. of a single representative exThe results clearly show that rGPRC6A is capable of homodimeriz-
ing as co-expression of HA- and c-myc-tagged rGPRC6A receptors
generates a FRET signal, whereas co-expression of c-myc-rGPRC6A
with the unrelated HA-tagged 5-HT2A receptor did not generate a
FRET signal (Fig. 4B). These experiments were performed on intact
cells demonstrating that the rGPRC6A receptors dimerize on the
cell surface. In parallel surface expression was determined for all
constructs demonstrating similar expression levels across the dif-
ferent receptor constructs (Fig. 4C). Next we wished to investigate
if the dimerization was mediated via a disulﬁde bridge. An align-
ment of rGPRC6A with other class C receptors (CaSR and
mGluR1–8) revealed two cysteines potentially involved in such a
disulﬁde bridge; C122 and C131 (Fig. 5A). Membrane preparations
from HEK-293T cells transfected with wild-type, C122A, C131A, or
C122A + C131A receptors were immunoblotted. The C122A mutant
displayed a band-pattern similar to wild-type receptor, but inter-
estingly we found distinct differences for both the C131A mutant
and the double mutant (Fig. 5B). For the C131A and the
C122A + C131A mutant the receptor dimer band was negligible
whereas the density of the monomeric bands were increased.
These data clearly show that when mutating C131 into an alanine,
the receptor is unable to preserve the dimeric structure upon Wes-
tern blotting probably due to loss of the disulﬁde bridge formation.
3.5. Mutation of cysteine residues on rGPRC6A affects receptor
expression
We next investigated the surface and total expression of the
cysteine mutants by ELISA. We found that both surface and total
expression levels of the C131A and especially the C122A + C131At GPRC6A with other family C receptors. Alignment of the loop region of rat GPRC6A
tors (mGluR1–8), which has previously been shown to harbor disulﬁde bridges in
ked in bold. GPRC6A contains two cysteines which, based on the alignment, could be
with default settings [51]. (B) Mutation of cysteine residues results in loss of dimer
lotted with anti-c-myc antibody. Wild-type (WT) receptor shows a dense band at
ot affect receptor composition, however when mutating C131A, either alone or with
d was intensiﬁed. Control cells were blank. Blot is representative for three repeated
ild-type (WT) and indicated rGPRC6A mutants. White bars are surface expression,
t four independent experiments performed in triplicates and are normalized to WT.
tt’s post-test (⁄P < 0.05, ⁄⁄⁄P < 0.001). (E) HEK-293T cells transiently transfected with
ed by the IP-One HTRF assay from Cisbio Bioassays (Codolet, France). Data are
periment performed in triplicates.
Table 3
L-Orn signaling parameter estimates for rGPRC6A Cys mutant receptors. IP1
accumulation was detected by the IP-One HTRF assay from Cisbio (Codolet, France).
No statistical signiﬁcant differences compared to WT were observed.
EC50
(lM)





WT 90 4.04 ± 0.05 100 100
C122A 55 4.26 ± 0.09 113 ± 6.8 103
C131A 92 4.04 ± 0.11 90 ± 14 64
C122A + C131A 181 3.74 ± 0.20 43 ± 17 24
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data therefore suggest that the disulﬁde bridge formed from
C131 does not affect the ability of the receptor to reach the cell
surface.
3.6. Mutation of cysteine residues on rGPRC6A affects receptor
function
It is widely known that receptor oligomerization can affect acti-
vation and signaling of GPCRs. Since we have shown that C131 is
important for rGPRC6A receptor dimerization, we wanted to inves-
tigate the role of this disulﬁde bridge in receptor signaling. Tran-
siently transfected cells were stimulated with L-Orn as described
earlier and IP1 accumulation was measured. The maximal
responses of the two single mutants, C122A and C131A, were not
markedly different from wild-type (113% ± 6.8 and 90% ± 14,
respectively), whereas L-Orn had a slightly increased potency at
the C122A mutant (EC50 of 55 lM compared to 90 lM for wild-
type, Fig. 5E and Table 3). The double C122A + C131A mutant had
a much lower activation level with a maximum response of
43 ± 17% and a twofold lower potency (EC50 of 181 lM) com-
pared to wild-type (Fig. 5E and Table 3).
4. Discussion
Studies of GPCRs have shown that their PTMs affect important
regulatory aspects such as: protein synthesis, trafﬁcking and sig-
naling. In this study we have investigated the role of N-glycosyla-
tion and disulﬁde bridging in rat GPRC6A via analyses of surface
expression, receptor activation and receptor size/migration on
SDS–PAGE. We found that seven asparagines (N121Q, N259Q,
N332Q, N378Q, N452Q, N555Q and N567Q) located in the ECD
carry N-glycans, all of which are located in the VFT domain except
N555 and N567, which are located in the CRD. Glycosylation of the
NXS/T consensus site occur with an average frequency of 67%
in vivo [2], which correlates nicely with our observation of seven
out of the nine proposed glycosylation sites to be modiﬁed. In
order to understand why residues N86 and N733 were not modi-
ﬁed we found that conservation of N85, but not N86 is seen
between class C GPCRs. N733 is located in the second extracellular
loop and probably not glycosylated because it would induce a con-
straint on the ﬂexibility of the seven transmembrane (7TM)
domain.
When we analyzed the different mutants by SDS–PAGE we
found that N86Q and N555Q mutants had lost one of the mono-
meric band when compared to the remaining mutants and wild-
type receptor. We speculate that the missing band corresponds
to the fully glycosylated form of the receptor, whereas the remain-
ing band corresponds to the core glycosylated form. This has pre-
viously been observed for other receptors such as the delta
opioid receptor [37]. Core glycosylation takes place in the endo-
plasmic reticulum (ER) whereas fully glycosylated and mature pro-
teins will have had to go through the Golgi apparatus [50]. Since
mutants N86Q and N555Q cannot become fully glycosylated thiscould explain their lack of surface expression and functional
response. We identiﬁed N555 as a direct target for N-glycosylation,
which suggest that modiﬁcation of this residue is important for
surface expression and functional response. N86 that did not carry
an N-glycan and the lack of expression may be caused by folding
difﬁculties due to the mutation itself or via disturbance of other
nearby PTMs causing a more unstable protein product.
In addition, we found that mutation of residue N567 resulted in
an increased functional response. N567 is located in the end of the
CRD just before the 7TM domain. It is possible that glycosylation of
this residue impede the ﬂexibility of this domain, thereby restrain-
ing signal transmission from the VFT to the 7TM domain. However
N555, which is also glycosylated, did not show the same effect on
activation even though it is also located in the CRD. Mutation of the
remaining four glycosylated residues did not alter cell surface
expression or functionality markedly.
Alignment of GPRC6A sequences from various species showed a
conserved putative N-glycosylation pattern in most species, of note
the seven detected N-glycosylation sites in rat are fully conserved
in human, gorilla and mouse (alignment not shown). Future stud-
ies will show if these sites are also N-glycosylated in these species
of GPRC6A.
The closest homolog of GPRC6A, the CaSR, has been shown to
carry eight N-glycans at residues N-90, -130, -261, -287, -446, -
468, -488, and -541 of which several affect surface expression
whereas none of them signiﬁcantly affect receptor signaling [43].
The eight sites are all located outside the CRD, which may explain
why receptor function is not altered upon mutation. Interestingly,
the study by Ray et al. [43] also showed that when mutating sev-
eral of these residues, glycosylation of three additional putative
sites could be seen, indicating that the process is highly dynamic
and that glycosylation of one site might affect the glycosylation
of other sites. Furthermore, introduction of glycosylation sites into
the GABAB receptor has demonstrated that glycosylation can also
modulate dimerization [47] and oligomerization [8]. It is therefore
important to keep in mind that rGPRC6A glycosylation in vivo can
differ from our ﬁndings.
It is evident that class C GPCRs are constitutive dimers at the
cell surface, yet this has never been shown experimentally for
GPRC6A although bands of dimeric weight have been shown on
Western blots [56]. Here we show for the ﬁrst time that GPRC6A
is able to form dimers. The time-resolved FRET studies demon-
strate that the receptor dimerizes at the cell surface of intact cells
(Fig. 4B) and the Western blot studies demonstrate that the recep-
tor dimer is covalently linked via a disulﬁde bridge (Fig. 5B). Con-
served disulﬁde bridges linking the VFT domains have been shown
to be involved in the dimerization of this class of receptors, how-
ever for mGluR5 and CaSR it has also been shown that additional
non-covalent interactions are involved in the dimerization
[46,58]. For CaSR it was even shown on Western blots under
non-reducing conditions that a large fraction of the receptor was
still present on the cell surface in the form of a dimer even after
mutating C129 and C131 [58]. Our data clearly demonstrate that
mutation of C131 results in loss of the dimeric form of the receptor
under non-reducing conditions upon Western blotting. C122A did
not change the dimer-monomer ratio, hence we suggest that only
C131 is involved in disulﬁde linkage of the rGPRC6A receptor. The
physiological role of the conserved cysteine residues for class C
receptors remain puzzling, since the receptors still can form
dimers at the cell surface and maintain functionality upon muta-
tion [19]. Studies on solubilized CaSR have shown that agonist
treatment increases the amount of dimeric receptors, suggesting
a dimer-stabilizing action of the agonists [53]. The agonist treat-
ment also protected the receptor from the action of reducing
agents and suggests the presence of conformationally sensitive
disulﬁde bridges [53]. This might lead to speculations that the
596 L. Nørskov-Lauritsen et al. / FEBS Letters 589 (2015) 588–597disulﬁde bridges help ﬁne-tune stability and/or conformation of
the receptors, however more research is needed to clarify this.
Surface and total expression of C122A and C131A mutants were
not impaired in agreement with what has been seen for CaSR
mutants [14,58] and the double mutant even showed higher
expression. This suggests that the disulﬁde bridge in rGPRC6A is
not required for surface expression of the receptor; rather it looks
like expression is increased when the disulﬁde bridge is absent.
Functional analysis showed that C131A had a similar pharmacolog-
ical proﬁle as WT, while L-Orn was slightly more potent on the
C122A mutant compared to the WT receptor. We have previously
shown, that the corresponding loop region in CaSR, where the cys-
teines involved in disulﬁde bridge formation are located (A116-
P136), is very sensitive to activation inducement by mutation
[21]. This may also be the case for GPRC6A and hence explain
why the C122A mutant responds more potently to L-Orn stimula-
tion. Mutating both residues lowered the response to 40% of
wild-type, indicating that the double mutant might impair proper
folding of the ECD. Studies have previously shown increased ligand
sensitivity for CaSR lacking the intermolecular cysteine linkers,
suggesting that a disulﬁde bridge might constrain the receptor in
the inactive form [45]. However, when mutating one of the cyste-
ines in CaSR (C129 or C131) this did not alter the functional
response level. Since the GPRC6A mutant C131A showed a similar
functional proﬁle to wild-type this indicates that disulﬁde linkage
is not required for correct receptor signaling. Conservation of C131
was veriﬁed through all GPRC6A species except guinea pig and
long-tailed chinchilla, supporting the idea that the human receptor
also forms a disulﬁde-linked dimer on the cell surface.
In conclusion, we have demonstrated that the rat GPRC6A
receptor is N-glycosylated at seven extracellular Asn residues,
forms a disulﬁde-linked homodimer via C131, and that some of
these residues regulate expression and functional signaling of the
receptor.
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